1984
Founded by Dr. Anji Reddy - The company’s first molecule was methyl-dopa, a hyper-tension drug that was unavail-able in India until 1984. The API has been supplied to leading pharma companies worldwide.
1991
From APIs to Formulations – Launch of Omez (Omeprazole). Dr. Reddy’s adds formulation capabilities
1995
Expansion into US, Europe, Russia and EM
2001
First Asia Pacific pharmaceutical company outside Japan to list on the New York Stock Exchange
2010
Dr. Reddy’s announced the launch of Amlodipine Benazepril in the US market.
Dr. Reddy’s launches the first biosimilar darbepoetin alfa in the world and brings relief to millions of anaemia patients and in India under the brand name 'Cresp®', the only one in India.
In the Active Ingredients business, the company filed 36 Drug Master Files (DMFs) in 2009-10. As on 31 March 2010, Dr. Reddy’s had cumulative filings of 378 DMFs, with 156 in the US.
2011
Dr. Reddy’s announced the launch of Pantoprazole Sodium delayed-released tablets.
Dr. Reddy’s launched Levocetirizine tablets, a bioequivalent generic version of Xyzal® in US market.
On October 23, Dr. Reddy’s received an approval and was awarded a 180-day of marketing exclusivity from US FDA for olanzapine 20 mg tablet.
2012
Dr. Reddy’s announced the launch of Atorvastatin Calcium Tablets, a bioequivalent generic version of LIPITOR® in the US market.
Dr. Reddy’s announced the launch of Metoprolol Succinate ER (Extended-Release) Tablet, a bioequivalent generic version of TopropXL® tablets in the US market.
2013
Dr. Reddy’s announced the launch of Zenatane™ (Isotretinoin Capsules USP), a therapeutic equivalent generic version of Accutane® in the US market.
Dr. Reddy’s announced the launch of Divalproex Sodium Extended-Release Tablets, USP, a therapeutic equivalent generic version of Depakote® ER tablet in the US market.
104 new generics products were launched.
577 DMFs were filed in FY2012-13.
2018
Dr. Reddy's Laboratories announces the launch of Hervycta® (trastuzumab biosimilar) in India.
Dr. Reddy's Laboratories receives approval for Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market.
2019
Dr. Reddy's Laboratories announces first-to-market launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market.
We are the First Indian Pharma Company to win the national tender for supply of one of the generic drugs (Olanzapine), in China.
2020
Dr. Reddy's Laboratories announces first-to-market launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe in the U.S. Market.
Dr. Reddy’s Laboratories announces the launch of FXR™ (obeticholic acid) in India.
Dr. Reddy's Laboratories announces the launch of AVIGAN® (Favipiravir) in India.
Dr. Reddy's Laboratories announces the launch of Redyx in India.
Our company played its part along with the rest of the pharma industry in the fight against COVID-19.
We combined our in-house efforts with an open-innovation model of partnerships to make available a portfolio that included a vaccine, and therapeutics for mild, moderate, and severe COVID-19.
Our focus on agility, access, and affordability helped us reach over 5 million patients during the pandemic, especially in low- and middle-income countries.
Our biggest manufacturing facility in Hyderabad was recognized by the World Economic Forum as part of its Global Lighthouse Network for leadership in the use of Industry 4.0 technologies.
Dr. Reddy's Foundation received a National Award from the President of India for the Empowerment of Persons with Disabilities.
We refreshed our ESG goals to make them bold, measurable, accountable, and central to business strategy.
We were named by the prestigious Science Magazine as among the Top 20 employers globally in pharma/biotech.
We launched Lenalidomide Capsules in the U.S. with two of six strengths eligible for first-to-file, 180-day exclusivity.
We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.
We launched Nerivio® in India for migraine management, marking our foray into digital therapeutics.
We entered into strategic collaborations for novel molecules - with the U.S.-based Coya Therapeutics for a novel combination biologic for ALS; with China-based Junshi Biosciences for Toripalimab; and with Jiangsu Hengrui for Pyrotinib.
We were included in the Bloomberg Gender-Equality Index for the 6th year in a row.
We diversified our offerings to patients – women’s healthcare in the U.S., consumer healthcare and our first-ever biosimilar in the UK, and vaccines in India.
We agreed with Nestlé India to form a joint venture to introduce health science nutraceutical products to consumers across India and other agreed territories.
We signed a definitive agreement with Haleon plc to acquire Nicotinell and its related portfolio in Nicotine Replacement Therapy, in a significant step towards building a global consumer healthcare business, outside of the US. This is our biggest acquisition yet.
